{
  "drugs": [
    {
      "drug": "Temozolomide",
      "proteins": [
        "MGMT"
      ],
      "mechanism": "DNA alkylation; MGMT-sensitive if methylated",
      "fda_status": "Approved (GBM std-of-care)",
      "category": "mainstream"
    },
    {
      "drug": "Pembrolizumab",
      "proteins": [
        "PD-1",
        "PD-L1"
      ],
      "mechanism": "Checkpoint blockade (limited GBM efficacy)",
      "fda_status": "Approved (other cancers)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Nivolumab",
      "proteins": [
        "PD-1",
        "PD-L1"
      ],
      "mechanism": "Checkpoint blockade (limited GBM efficacy)",
      "fda_status": "Approved (other cancers)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Sevabertinib",
      "proteins": [
        "EGFR"
      ],
      "mechanism": "EGFR/HER2 kinase inhibition",
      "fda_status": "Accelerated (NSCLC; GBM candidate)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Erlotinib",
      "proteins": [
        "EGFR"
      ],
      "mechanism": "EGFR tyrosine kinase inhibition",
      "fda_status": "Approved (other cancers; GBM failed)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Gefitinib",
      "proteins": [
        "EGFR"
      ],
      "mechanism": "EGFR tyrosine kinase inhibition",
      "fda_status": "Approved (other cancers)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Everolimus",
      "proteins": [
        "PTEN"
      ],
      "mechanism": "mTOR inhibition (PI3K/PTEN pathway)",
      "fda_status": "Approved (repurposed for GBM)",
      "category": "mainstream"
    },
    {
      "drug": "BI-2536",
      "proteins": [
        "TP53"
      ],
      "mechanism": "PLK1 inhibition (TP53-mutant selective)",
      "fda_status": "Candidate (preclinical)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Bortezomib",
      "proteins": [
        "PTEN"
      ],
      "mechanism": "Proteasome inhibition, indirect interaction",
      "fda_status": "Approved (multiple myeloma)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Fludarabine",
      "proteins": [
        "TP53"
      ],
      "mechanism": "Induces DNA damage in TP53-mutant cells",
      "fda_status": "Approved (CLL)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Seliciclib",
      "proteins": [
        "TP53"
      ],
      "mechanism": "Inhibits cell cycle progression in TP53/PTEN-dysregulated GBM",
      "fda_status": "Advanced trials (not fully approved)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "AT-9283",
      "proteins": [
        "EGFR"
      ],
      "mechanism": "Disrupts mitosis and DNA repair in EGFR/TP53-altered cells",
      "fda_status": "In trials",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Litronesib",
      "proteins": [
        "TP53"
      ],
      "mechanism": "Mitotic arrest in rapidly dividing GBM cells with PTEN/TP53 loss",
      "fda_status": "In trials",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Olaparib",
      "proteins": [
        "MGMT",
        "TP53"
      ],
      "mechanism": "Synthetic lethality in homologous recombination-deficient GBM",
      "fda_status": "Approved (ovarian cancer)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Afatinib",
      "proteins": [
        "EGFR"
      ],
      "mechanism": "Blocks EGFR-driven PI3K/AKT signaling",
      "fda_status": "Approved (NSCLC)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Metformin",
      "proteins": [
        "PTEN",
        "EGFR"
      ],
      "mechanism": "Suppresses metabolic reprogramming and invasion in PTEN-deficient cells",
      "fda_status": "Approved (type 2 diabetes)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Atenolol",
      "proteins": [
        "EGFR",
        "PD-L1"
      ],
      "mechanism": "Reduces adrenergic stress-induced PD-L1 expression and invasion",
      "fda_status": "Approved (hypertension)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Disulfiram",
      "proteins": [
        "MGMT",
        "TP53"
      ],
      "mechanism": "Proteotoxic stress and DNA repair inhibition in MGMT-high tumors",
      "fda_status": "Approved (alcohol dependence)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Thalidomide",
      "proteins": [
        "PD-1",
        "PD-L1"
      ],
      "mechanism": "Immune modulation and anti-angiogenesis targeting PD-L1 microenvironment",
      "fda_status": "Approved (multiple myeloma)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Copanlisib",
      "proteins": [
        "PTEN"
      ],
      "mechanism": "Upstream PI3K inhibition",
      "fda_status": "In trials",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Dabrafenib",
      "proteins": [],
      "mechanism": "BRAF-targeted",
      "fda_status": "Approved",
      "category": "mainstream"
    },
    {
      "drug": "Trametinib",
      "proteins": [],
      "mechanism": "BRAF-targeted",
      "fda_status": "Approved",
      "category": "mainstream"
    }
  ],
  "cancer_type": "glioblastoma",
  "protein_targets": [
    "MGMT",
    "PD-1",
    "PD-L1",
    "EGFR",
    "PTEN",
    "TP53"
  ]
}